Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 14/20 | 0.67 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23828253 | 0.80 | CFTR (1.00) | CFTRBAZ2BKDR | |
| SCHEMBL23828315 | 0.73 | CFTR (0.46) | CFTR | |
| SCHEMBL23828255 | 0.70 | CFTR (1.00) | CFTRBAZ2B | |
| SCHEMBL31020953 | 0.69 | CFTR (1.00) | CFTRBAZ2BKDR | |
| SCHEMBL23828284 | 0.69 | CFTR (1.00) | CFTRBAZ2BKDR | |
| SCHEMBL21617986 | 0.69 | CFTR (0.68) | CFTR | |
| SCHEMBL31020947 | 0.68 | CFTR (0.78) | CFTRBAZ2BKMT2AMEN1ALDH1A1 | |
| SCHEMBL23828257 | 0.68 | CFTR (0.78) | CFTRBAZ2BKMT2AMEN1ALDH1A1 | |
| SCHEMBL23828285 | 0.67 | CFTR (0.75) | CFTRBAZ2BKDR | |
| SCHEMBL23828307 | 0.67 | CFTR (0.72) | CFTRBAZ2BKDRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999734-B2 | Compounds and compositions for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-06-04 | — | — | US | claimed |
| EP-3820867-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2023-09-13 | — | — | EP | claimed |
| US-20210292324-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2021-09-23 | — | — | US | claimed |
| US-11999734-B2 | Compounds and compositions for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-06-04 | — | — | US | disclosed |
| EP-3820867-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2023-09-13 | — | — | EP | disclosed |
| US-20210292324-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999734-B2 | Compounds and compositions for the treatment of cystic fibrosis | CFTR, ABCB11, ABCC5 | CFTR 1/4885BAZ2B 4498/4885KDR 4816/4885 |
| US-20210292324-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | CFTR 1/4885BAZ2B 4498/4885KDR 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.